Cyclo Therapeutics Key Executives
This section highlights Cyclo Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Cyclo Therapeutics
(Showing 0 of )
Cyclo Therapeutics Earnings
This section highlights Cyclo Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
$0.72
Stock Price
$23.59M
Market Cap
8
Employees
Gainesville, FL
Location
Financial Statements
Access annual & quarterly financial statements for Cyclo Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $1.08M | $1.38M | $1.59M | $903.38K | $1.01M |
| Cost of Revenue | $98.46K | $138.93K | $156.08K | $66.40K | $75.49K |
| Gross Profit | $977.95K | $1.24M | $1.43M | $836.98K | $931.71K |
| Gross Profit Ratio | 90.85% | 89.90% | 90.16% | 92.65% | 92.50% |
| Research and Development Expenses | $14.18M | $9.00M | $9.15M | $6.10M | $4.87M |
| General and Administrative Expenses | $5.66M | $7.81M | $6.50M | $3.68M | $3.43M |
| Selling and Marketing Expenses | $3.90K | $13.06K | $18.34K | $5.01K | $5.88K |
| Selling General and Administrative Expenses | $6.83M | $7.82M | $6.52M | $3.68M | $3.44M |
| Other Expenses | $- | $30.50K | $27.54K | $19.95K | $13.98K |
| Operating Expenses | $21.04M | $16.85M | $15.70M | $9.80M | $8.32M |
| Cost and Expenses | $21.13M | $16.99M | $15.85M | $9.86M | $8.40M |
| Interest Income | $- | $12.47K | $3.40K | $19.80K | $12.03K |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $19.28K | $19.48K | $16.83K | $12.76K | $5.68K |
| EBITDA | $-20.03M | $-15.60M | $-14.27M | $-8.95M | $-7.39M |
| EBITDA Ratio | -1860.90% | -1134.09% | -899.88% | -990.58% | -733.23% |
| Operating Income | $-20.05M | $-15.61M | $-14.27M | $-8.96M | $-7.39M |
| Operating Income Ratio | -1862.69% | -1134.76% | -899.77% | -991.85% | -733.80% |
| Total Other Income Expenses Net | $-7.25K | $171.00K | $3.40K | $19.80K | $12.03K |
| Income Before Tax | $-20.06M | $-15.45M | $-14.29M | $-8.94M | $-7.53M |
| Income Before Tax Ratio | -1863.36% | -1123.08% | -900.94% | -989.80% | -747.87% |
| Income Tax Expense | $- | $-171.00K | $18.52K | $-18.53K | $141.75K |
| Net Income | $-20.06M | $-15.28M | $-14.31M | $-8.92M | $-7.67M |
| Net Income Ratio | -1863.36% | -1110.65% | -902.10% | -987.75% | -761.94% |
| EPS | $-1.23 | $-1.81 | $-2.25 | $-5.58 | $-7.09 |
| EPS Diluted | $-1.23 | $-1.81 | $-2.25 | $-5.58 | $-7.09 |
| Weighted Average Shares Outstanding | 16.33M | 8.44M | 6.37M | 1.60M | 1.08M |
| Weighted Average Shares Outstanding Diluted | 16.33M | 8.44M | 6.37M | 1.60M | 1.08M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $233.77K | $123.10K | $202.45K | $311.40K | $495.48K | $117.12K | $152.41K | $186.80K | $452.17K | $541.89K | $194.90K | $585.12K | $403.92K | $238.59K | $358.13K | $145.59K | $222.46K | $209.59K | $325.73K | $227.36K |
| Cost of Revenue | $16.80K | $931.13K | $836.48K | $876.55K | $38.77K | $19.91K | $10.20K | $15.77K | $33.03K | $73.67K | $16.46K | $68.66K | $22.67K | $30.16K | $34.60K | $15.44K | $11.58K | $12.95K | $26.43K | $12.66K |
| Gross Profit | $216.97K | $-808.02K | $-634.03K | $-565.15K | $456.71K | $97.21K | $142.22K | $171.04K | $419.13K | $468.22K | $178.44K | $516.46K | $381.25K | $208.43K | $323.54K | $130.15K | $210.88K | $196.65K | $299.30K | $214.70K |
| Gross Profit Ratio | 92.81% | -656.37% | -313.18% | -181.49% | 92.18% | 83.00% | 93.31% | 91.56% | 92.69% | 86.41% | 91.55% | 88.27% | 94.39% | 87.36% | 90.34% | 89.39% | 94.80% | 93.82% | 91.89% | 94.43% |
| Research and Development Expenses | $5.49M | $3.49M | $2.85M | $4.14M | $3.47M | $3.17M | $3.40M | $3.18M | $2.86M | $1.87M | $1.08M | $1.41M | $1.84M | $2.64M | $3.26M | $1.24M | $1.09M | $1.71M | $2.06M | $1.80M |
| General and Administrative Expenses | $2.16M | $1.41M | $1.56M | $1.40M | $1.53M | $1.27M | $1.74M | $1.95M | $1.80M | $2.04M | $2.02M | $1.85M | $2.39M | $1.16M | $1.10M | $1.57M | $555.06K | $678.25K | $874.95K | $893.33K |
| Selling and Marketing Expenses | $441 | $501 | $373 | $1.38K | $1.30K | $403 | $819 | $1.24K | $2.20K | $5.10K | $4.52K | $13.18K | $2.36K | $1.28K | $1.51K | $1.43K | $543 | $1.17K | $1.86K | $1.91K |
| Selling General and Administrative Expenses | $2.37M | $1.41M | $1.63M | $933.03K | $1.53M | $1.28M | $1.75M | $1.95M | $1.80M | $2.04M | $2.02M | $1.86M | $2.40M | $1.16M | $1.10M | $1.57M | $555.61K | $679.41K | $876.82K | $895.24K |
| Other Expenses | $646.26K | $-79.03K | $540.43K | $-2.31M | $1.16M | $1.15M | $6.07K | $5.71K | $7.31K | $8.42K | $9.06K | $9.18K | $6.63K | $6.51K | $5.22K | $6.08K | $4.53K | $4.43K | $4.92K | $5.50K |
| Operating Expenses | $8.50M | $4.83M | $4.48M | $5.08M | $5.22M | $4.73M | $5.15M | $5.14M | $4.67M | $3.92M | $3.11M | $3.29M | $4.24M | $3.81M | $4.36M | $2.81M | $1.65M | $2.40M | $2.94M | $2.70M |
| Cost and Expenses | $8.52M | $5.76M | $5.31M | $5.95M | $5.26M | $4.75M | $5.16M | $5.16M | $4.70M | $4.00M | $3.13M | $3.36M | $4.26M | $3.84M | $4.40M | $2.83M | $1.66M | $2.41M | $2.97M | $2.71M |
| Interest Income | $- | $- | $- | $- | $- | $- | $47 | $2.48K | $1.62K | $4.03K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- | $- | $- | $184.97K | $- | $- | $162.87B | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $2.18K | $2.18K | $2.18K | $4.82K | $4.82K | $4.82K | $4.82K | $4.87K | $5.13K | $4.74K | $4.74K | $4.21K | $4.21K | $4.86K | $3.55K | $3.41K | $3.12K | $3.12K | $3.12K | $1.42K |
| EBITDA | $-8.29M | $-5.64M | $-5.11M | $-5.64M | $-4.76M | $-4.63M | $-5.00M | $-4.98M | $-4.24M | $-3.45M | $-2.93M | $-2.79M | $-3.85M | $-3.60M | $-4.03M | $-2.68M | $-1.43M | $-2.20M | $-2.64M | $-2.48M |
| EBITDA Ratio | -3545.02% | -4577.99% | -2522.63% | -1810.44% | -961.22% | -3951.68% | -3282.12% | -2664.86% | -938.45% | -636.90% | -1503.16% | -476.52% | -954.35% | -1507.02% | -1126.32% | -1839.50% | -644.10% | -1049.07% | -810.15% | -1090.69% |
| Operating Income | $-8.29M | $-5.64M | $-5.11M | $-5.64M | $-4.77M | $-4.63M | $-5.01M | $-4.97M | $-4.25M | $-3.46M | $-2.93M | $-2.79M | $-3.86M | $-3.60M | $-4.04M | $-2.68M | $-1.44M | $-2.20M | $-2.64M | $-2.64M |
| Operating Income Ratio | -3545.95% | -4577.99% | -2523.71% | -1811.99% | -962.20% | -3955.79% | -3285.28% | -2661.97% | -939.59% | -637.78% | -1505.59% | -477.40% | -955.40% | -1509.05% | -1127.31% | -1841.84% | -645.50% | -1050.56% | -811.10% | -1160.20% |
| Total Other Income Expenses Net | $-543.50K | $-345.56K | $766.19K | $114 | $-3.89K | $-3.51K | $47 | $2.48K | $1.62K | $4.03K | $162.87K | $930 | $-1.24K | $3.05K | $661 | $1.85K | $390 | $9.51K | $8.05K | $2.85K |
| Income Before Tax | $-8.83M | $-5.98M | $-4.34M | $-5.64M | $-4.77M | $-4.64M | $-5.01M | $-4.98M | $-4.25M | $-3.45M | $-2.77M | $-2.79M | $-3.86M | $-3.60M | $-4.04M | $-2.68M | $-1.44M | $-2.19M | $-2.63M | $-2.64M |
| Income Before Tax Ratio | -3778.44% | -4858.70% | -2145.25% | -1811.95% | -962.98% | -3958.79% | -3285.25% | -2666.14% | -939.23% | -637.03% | -1422.03% | -477.24% | -955.70% | -1507.77% | -1127.13% | -1840.57% | -645.33% | -1046.02% | -808.63% | -1158.95% |
| Income Tax Expense | $- | $- | $3 | $1 | $3.89K | $3.51K | $-94 | $-169.38K | $-1.62K | $-4.03K | $-162.87B | $21.00K | $1.24K | $-3.05K | $-661 | $-1.85K | $-390 | $-8.24K | $-8.05K | $150.93K |
| Net Income | $-8.83M | $-5.98M | $-4.34M | $-5.64M | $-4.77M | $-4.64M | $-5.01M | $-4.81M | $-4.25M | $-3.45M | $162.86B | $-2.79M | $-3.86M | $-3.60M | $-4.04M | $-2.68M | $-1.44M | $-2.19M | $-2.63M | $-2.64M |
| Net Income Ratio | -3778.44% | -4858.70% | -2145.25% | -1811.95% | -962.98% | -3958.79% | -3285.19% | -2575.47% | -938.87% | -636.29% | 83560741.91% | -477.24% | -955.70% | -1507.77% | -1127.13% | -1840.57% | -645.33% | -1046.02% | -808.63% | -1158.95% |
| EPS | $-0.31 | $-0.21 | $-0.15 | $-0.23 | $-0.29 | $-0.33 | $-0.46 | $-0.57 | $-0.50 | $-0.41 | $19361.00 | $-0.43 | $-0.60 | $-0.56 | $-0.76 | $-0.50 | $-0.85 | $-1.60 | $-2.17 | $-2.20 |
| EPS Diluted | $-0.31 | $-0.21 | $-0.15 | $-0.23 | $-0.29 | $-0.33 | $-0.46 | $-0.57 | $-0.50 | $-0.41 | $19361.00 | $-0.43 | $-0.60 | $-0.56 | $-0.76 | $-0.50 | $-0.85 | $-1.55 | $-2.17 | $-2.18 |
| Weighted Average Shares Outstanding | 28.73M | 28.64M | 28.59M | 24.87M | 16.19M | 14.04M | 11.00M | 8.46M | 8.45M | 8.42M | 8.41M | 6.45M | 6.45M | 6.37M | 5.33M | 5.33M | 1.70M | 1.37M | 1.22M | 1.20M |
| Weighted Average Shares Outstanding Diluted | 28.73M | 28.64M | 28.59M | 24.87M | 16.19M | 14.04M | 11.00M | 8.46M | 8.45M | 8.42M | 8.41M | 6.45M | 6.45M | 6.37M | 5.33M | 5.33M | 1.70M | 1.42M | 1.22M | 1.21M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $9.25M | $1.54M | $16.61M | $12.85M | $2.78M |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $9.25M | $1.54M | $16.61M | $12.85M | $2.78M |
| Net Receivables | $122.38K | $54.99K | $539.09K | $111.79K | $182.49K |
| Inventory | $254.35K | $254.49K | $227.44K | $237.91K | $242.63K |
| Other Current Assets | $2.69M | $4.61M | $2.06M | $854.43K | $749.23K |
| Total Current Assets | $12.32M | $4.16M | $19.44M | $14.05M | $3.96M |
| Property Plant Equipment Net | $929.28K | $56.66K | $77.22K | $87.92K | $64.56K |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $7.28K | $49.81K | $90.60K |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $-56.66K | $- | $- | $- |
| Total Non-Current Assets | $929.28K | $56.66K | $84.50K | $137.73K | $155.16K |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $13.25M | $4.22M | $19.52M | $14.19M | $4.11M |
| Account Payables | $4.86M | $2.23M | $3.68M | $3.54M | $3.12M |
| Short Term Debt | $1.01M | $- | $152.96K | $131.51K | $32.77K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $-3.68M | $-3.54M | $-3.12M |
| Other Current Liabilities | $2.60M | $1.25M | $- | $- | $-16.39K |
| Total Current Liabilities | $8.47M | $3.48M | $3.83M | $3.67M | $3.14M |
| Long Term Debt | $22.48K | $- | $18.03K | $62.93K | $72.25K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $-36.13K |
| Total Non-Current Liabilities | $22.48K | $3.48M | $18.03K | $62.93K | $36.13K |
| Other Liabilities | $- | $-3.48M | $- | $- | $- |
| Total Liabilities | $8.49M | $3.48M | $3.85M | $3.74M | $3.18M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $2.86K | $849 | $841 | $477 | $12.15K |
| Retained Earnings | $-83.86M | $-63.80M | $-48.35M | $-34.06M | $-25.12M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $- |
| Other Total Stockholders Equity | $88.61M | $64.53M | $64.02M | $44.51M | $26.04M |
| Total Stockholders Equity | $4.76M | $734.54K | $15.67M | $10.45M | $935.98K |
| Total Equity | $4.76M | $734.54K | $15.67M | $10.45M | $935.98K |
| Total Liabilities and Stockholders Equity | $13.25M | $4.22M | $19.52M | $14.19M | $4.11M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $13.25M | $4.22M | $19.52M | $14.19M | $4.11M |
| Total Investments | $- | $- | $7.28K | $49.81K | $90.60K |
| Total Debt | $1.03M | $- | $170.99K | $194.44K | $52.51K |
| Net Debt | $-8.21M | $-1.54M | $-16.44M | $-12.65M | $-2.73M |
Balance Sheet Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $928.01K | $1.12M | $3.00M | $9.25M | $1.80M | $841.53K | $915.18K | $1.54M | $4.29M | $7.45M | $11.80M | $16.61M | $8.44M | $11.46M | $15.51M | $12.85M | $2.24M | $1.01M | $933.46K | $2.78M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $928.01K | $1.12M | $3.00M | $9.25M | $1.80M | $841.53K | $915.18K | $1.54M | $4.29M | $7.45M | $11.80M | $16.61M | $8.44M | $11.46M | $15.51M | $12.85M | $2.24M | $1.01M | $933.46K | $2.78M |
| Net Receivables | $187.68K | $83.74K | $71.32K | $122.38K | $303.76K | $88.39K | $131.22K | $54.99K | $394.57K | $438.69K | $157.72K | $539.09K | $399.93K | $224.48K | $220.17K | $111.79K | $124.56K | $200.29K | $207.88K | $182.49K |
| Inventory | $236.11K | $241.03K | $242.53K | $254.35K | $209.75K | $236.64K | $244.50K | $254.49K | $271.14K | $260.61K | $221.06K | $227.44K | $253.80K | $268.93K | $257.83K | $237.91K | $421.32K | $216.61K | $228.77K | $242.63K |
| Other Current Assets | $1.90M | $3.00M | $3.26M | $2.69M | $6.39M | $6.76M | $5.41M | $4.61M | $6.93M | $3.62M | $3.67M | $2.06M | $1.90M | $2.16M | $2.04M | $854.43K | $1.19M | $662.83K | $727.15K | $749.23K |
| Total Current Assets | $3.26M | $4.45M | $6.57M | $12.32M | $5.51M | $4.55M | $3.99M | $4.16M | $8.42M | $11.78M | $15.85M | $19.44M | $10.99M | $14.12M | $18.02M | $14.05M | $3.97M | $2.09M | $2.10M | $3.96M |
| Property Plant Equipment Net | $26.64K | $267.72K | $593.82K | $929.28K | $85.55K | $94.70K | $103.76K | $56.66K | $65.73K | $64.78K | $73.93K | $77.22K | $85.83K | $94.45K | $81.22K | $87.92K | $95.67K | $102.95K | $107.82K | $64.56K |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $7.28K | $18.52K | $28.36K | $38.94K | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $1.97M | $- | $- | $- | $- | $-94.70K | $-103.76K | $-56.66K | $-65.73K | $-64.78K | $- | $- | $- | $- | $- | $49.81K | $64.73K | $71.26K | $80.98K | $90.60K |
| Total Non-Current Assets | $2.00M | $267.72K | $593.82K | $929.28K | $85.55K | $94.70K | $103.76K | $56.66K | $65.73K | $64.78K | $73.93K | $84.50K | $104.35K | $122.81K | $120.16K | $137.73K | $160.40K | $174.22K | $188.80K | $155.16K |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $5.25M | $4.72M | $7.16M | $13.25M | $5.60M | $4.64M | $4.10M | $4.22M | $8.49M | $11.84M | $15.92M | $19.52M | $11.10M | $14.24M | $18.14M | $14.19M | $4.13M | $2.26M | $2.29M | $4.11M |
| Account Payables | $5.02M | $3.86M | $3.67M | $4.86M | $6.60M | $6.08M | $4.48M | $2.23M | $2.87M | $2.09M | $2.86M | $3.68M | $3.29M | $2.93M | $3.63M | $3.54M | $4.46M | $3.98M | $3.94M | $3.12M |
| Short Term Debt | $12.20M | $2.98M | $647.56K | $2.02M | $35.95K | $34.93K | $33.94K | $- | $9.96K | $19.61K | $29.12K | $152.96K | $125.72K | $104.90K | $78.47K | $131.51K | $116.18K | $94.81K | $33.43K | $32.77K |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $369.14K | $- | $- | $- | $-6.60M | $-6.08M | $-4.48M | $- | $-2.87M | $-2.09M | $-2.86M | $-3.68M | $-3.29M | $-3.02M | $-3.63M | $-3.54M | $-4.46M | $-3.98M | $-3.94M | $-3.12M |
| Other Current Liabilities | $1.50M | $2.98M | $2.22M | $1.59M | $-17.97K | $-17.47K | $-16.97K | $1.25M | $-4.98K | $-9.80K | $-14.56K | $- | $- | $- | $- | $- | $-14.38K | $-16.97K | $-16.72K | $-16.39K |
| Total Current Liabilities | $18.72M | $9.83M | $6.54M | $8.47M | $6.62M | $6.10M | $4.50M | $3.48M | $2.88M | $2.10M | $2.88M | $3.83M | $3.42M | $3.04M | $3.71M | $3.67M | $4.56M | $4.06M | $3.95M | $3.14M |
| Long Term Debt | $7.14K | $12.38K | $17.51K | $44.97K | $54.52K | $63.88K | $73.05K | $- | $- | $- | $- | $18.03K | $49.89K | $82.03K | $112.94K | $62.93K | $122.86K | $125.10K | $63.54K | $36.13K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $-22.48K | $-27.26K | $-31.94K | $-36.53K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-25.88K | $- | $-31.77K | $- |
| Total Non-Current Liabilities | $7.14K | $12.38K | $17.51K | $22.48K | $27.26K | $31.94K | $36.53K | $3.48M | $2.88M | $2.10M | $2.88M | $18.03K | $49.89K | $82.03K | $112.94K | $62.93K | $96.98K | $125.10K | $31.77K | $36.13K |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $-3.48M | $-2.88M | $-2.10M | $-2.88M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $18.73M | $9.84M | $6.55M | $8.49M | $6.65M | $6.13M | $4.54M | $3.48M | $2.88M | $2.10M | $2.88M | $3.85M | $3.47M | $3.12M | $3.82M | $3.74M | $4.66M | $4.18M | $3.98M | $3.18M |
| Preferred Stock | $- | $- | $- | $0 | $0 | $- | $- | $- | $1 | $1 | $- | $- | $- | $1 | $0 | $- | $- | $- | $- | $- |
| Common Stock | $2.88K | $2.87K | $2.86K | $2.86K | $1.94K | $1.53K | $1.06K | $849 | $846 | $844 | $842 | $841 | $646 | $644 | $635 | $477 | $16.99K | $14.15K | $12.15K | $12.15K |
| Retained Earnings | $-103.01M | $-94.18M | $-88.20M | $-83.86M | $-78.21M | $-73.44M | $-68.81M | $-63.80M | $-58.82M | $-54.57M | $-51.12M | $-48.35M | $-45.56M | $-41.70M | $-38.10M | $-34.06M | $-31.38M | $-29.95M | $-27.75M | $-25.12M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $-0 | $-0 | $- | $- | $- | $0 | $0 | $- | $- | $- | $0 | $-0 | $- | $- | $- | $- | $- |
| Other Total Stockholders Equity | $89.54M | $89.06M | $88.81M | $88.61M | $77.16M | $71.96M | $68.37M | $64.53M | $64.43M | $64.31M | $64.17M | $64.02M | $53.18M | $52.82M | $52.42M | $44.51M | $30.84M | $28.01M | $26.04M | $26.04M |
| Total Stockholders Equity | $-13.47M | $-5.12M | $610.01K | $4.76M | $-1.05M | $-1.48M | $-438.88K | $734.54K | $5.61M | $9.74M | $13.05M | $15.67M | $7.63M | $11.13M | $14.32M | $10.45M | $-524.53K | $-1.92M | $-1.70M | $935.98K |
| Total Equity | $-13.47M | $-5.12M | $610.01K | $4.76M | $-1.05M | $-1.48M | $-438.88K | $734.54K | $5.61M | $9.74M | $13.05M | $15.67M | $7.63M | $11.13M | $14.32M | $10.45M | $-524.53K | $-1.92M | $-1.70M | $935.98K |
| Total Liabilities and Stockholders Equity | $5.25M | $4.72M | $7.16M | $13.25M | $5.60M | $4.64M | $4.10M | $4.22M | $8.49M | $11.84M | $15.92M | $19.52M | $11.10M | $14.24M | $18.14M | $14.19M | $4.13M | $2.26M | $2.29M | $4.11M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $5.25M | $4.72M | $7.16M | $13.25M | $5.60M | $4.64M | $4.10M | $4.22M | $8.49M | $11.84M | $15.92M | $19.52M | $11.10M | $14.24M | $18.14M | $14.19M | $4.13M | $2.26M | $2.29M | $4.11M |
| Total Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $7.28K | $18.52K | $28.36K | $38.94K | $- | $- | $- | $- | $- |
| Total Debt | $12.21M | $3.00M | $665.06K | $1.03M | $45.23K | $49.41K | $53.50K | $- | $4.98K | $9.80K | $14.56K | $170.99K | $175.61K | $186.93K | $191.41K | $194.44K | $198.78K | $202.94K | $48.49K | $52.51K |
| Net Debt | $11.28M | $1.88M | $-2.33M | $-8.21M | $-1.76M | $-792.12K | $-861.68K | $-1.54M | $-4.29M | $-7.44M | $-11.78M | $-16.44M | $-8.27M | $-11.28M | $-15.32M | $-12.65M | $-2.04M | $-805.41K | $-884.97K | $-2.73M |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $-20.06M | $-15.45M | $-14.29M | $-8.94M | $-7.53M |
| Depreciation and Amortization | $19.28K | $19.48K | $16.83K | $12.76K | $5.68K |
| Deferred Income Tax | $- | $- | $- | $-74.70K | $- |
| Stock Based Compensation | $736.91K | $513.57K | $470.88K | $271.31K | $436.70K |
| Change in Working Capital | $3.06M | $-48.15K | $-1.23M | $117.35K | $487.40K |
| Accounts Receivables | $-67.39K | $427.85K | $-444.02K | $72.41K | $-63.38K |
| Inventory | $-52.78K | $-27.05K | $10.47K | $4.72K | $160.64K |
| Accounts Payables | $3.25M | $-200.39K | $-794.42K | $39.80K | $387.99K |
| Other Working Capital | $-62.29K | $-248.56K | $-297 | $412 | $2.16K |
| Other Non Cash Items | $52.92K | $-148.25K | $21.93K | $74.70K | $13.27K |
| Net Cash Provided by Operating Activities | $-16.19M | $-15.11M | $-15.01M | $-8.54M | $-6.59M |
| Investments in Property Plant and Equipment | $-2.42K | $-15.09K | $-22.50K | $-53.13K | $-1.32K |
| Acquisitions Net | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $53.26K | $37.32K | $39.08K | $37.46K |
| Net Cash Used for Investing Activities | $-2.42K | $38.17K | $14.82K | $-14.05K | $36.13K |
| Debt Repayment | $- | $6.78K | $-6.78K | $158.52K | $- |
| Common Stock Issued | $9.74M | $159.51K | $18.76M | $18.46M | $6.99M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $14.15M | $- | $- | $- | $130.06K |
| Net Cash Used Provided by Financing Activities | $23.89M | $6.78K | $18.76M | $18.62M | $7.12M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $7.70M | $-15.07M | $3.77M | $10.06M | $566.31K |
| Cash at End of Period | $9.25M | $1.54M | $16.61M | $12.85M | $2.78M |
| Cash at Beginning of Period | $1.54M | $16.61M | $12.85M | $2.78M | $2.22M |
| Operating Cash Flow | $-16.19M | $-15.11M | $-15.01M | $-8.54M | $-6.59M |
| Capital Expenditure | $-2.42K | $-15.09K | $-22.50K | $-53.13K | $-1.32K |
| Free Cash Flow | $-16.19M | $-15.13M | $-15.03M | $-8.59M | $-6.59M |
Cash Flow Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-8.83M | $-5.98M | $-4.34M | $-5.64M | $-4.77M | $-4.64M | $-5.01M | $-4.98M | $-4.25M | $-3.45M | $-2.77M | $-2.79M | $-3.86M | $-3.60M | $-4.04M | $-2.68M | $-1.44M | $-2.19M | $-2.63M | $-2.64M |
| Depreciation and Amortization | $2.18K | $2.18K | $2.18K | $4.82K | $4.82K | $4.82K | $4.82K | $4.87K | $5.13K | $4.74K | $4.74K | $4.21K | $4.21K | $4.86K | $3.55K | $3.41K | $3.12K | $3.12K | $3.12K | $1.42K |
| Deferred Income Tax | $- | $- | $- | $-61.76K | $126.25K | $1.45M | $834.39K | $- | $- | $- | $- | $- | $- | $- | $- | $-117.35K | $- | $- | $- | $- |
| Stock Based Compensation | $-17.81K | $365.86K | $173.22K | $257.77K | $202.04K | $185.44K | $91.67K | $215.52K | $119.30K | $144.02K | $147.74K | $-206.86K | $305.83K | $271.31K | $50.30K | $251.93K | $5.32K | $6.84K | $7.22K | $8.74K |
| Change in Working Capital | $972.19K | $1.15M | $-2.12M | $1.03M | $523.29K | $967.49K | $540.36K | $2.09M | $962.74K | $-1.05M | $-2.05M | $361.44K | $473.07K | $-1.12M | $-944.05K | $-637.08K | $-181.21K | $121.23K | $814.40K | $391.58K |
| Accounts Receivables | $-103.94K | $-12.41K | $51.06K | $181.38K | $-215.37K | $42.83K | $-76.23K | $307.55K | $37.12K | $-291.56K | $374.74K | $-160.18K | $-172.43K | $-10.57K | $-100.85K | $14.49K | $75.73K | $7.59K | $-25.39K | $-107.69K |
| Inventory | $4.92K | $1.50K | $11.82K | $-97.52K | $26.89K | $7.85K | $9.99K | $16.65K | $-10.52K | $-39.56K | $6.38K | $26.36K | $15.13K | $-11.10K | $-19.93K | $183.41K | $-204.72K | $12.16K | $13.86K | $128.22K |
| Accounts Payables | $-107.86K | $955.20K | $-1.57M | $121.79K | $711.62K | $916.65K | $1.00M | $-978.09K | $777.70K | $-771.50K | $-816.40K | $408.25K | $630.51K | $-1.10M | $358.56K | $145.00K | $535.73K | $101.29K | $803.63K | $1.12M |
| Other Working Capital | $1.18M | $201.93K | $-612.69K | $826.37K | $155 | $155 | $-395.33K | $2.75M | $158.45K | $50.10K | $-1.62M | $87.02K | $-137 | $-70 | $-1.18M | $-979.98K | $-587.95K | $186 | $22.31K | $-747.98K |
| Other Non Cash Items | $-316.02K | $618.87K | $1.79M | $114.68K | $-126.25K | $-1.45M | $-834.39K | $-80.98K | $9.00K | $41.26K | $-117.52K | $21.93K | $158.24K | $1.27M | $-180.39K | $117.35K | $473.48K | $27.36K | $813.25K | $13.27K |
| Net Cash Provided by Operating Activities | $-8.19M | $-3.85M | $-6.18M | $-4.29M | $-4.04M | $-3.48M | $-4.37M | $-2.75M | $-3.18M | $-4.36M | $-4.83M | $-2.61M | $-3.03M | $-4.44M | $-4.93M | $-3.06M | $-1.61M | $-2.06M | $-1.81M | $-2.22M |
| Investments in Property Plant and Equipment | $-3.85M | $3.85M | $- | $-2.42K | $- | $- | $- | $15.09K | $-10.49K | $- | $-4.60K | $22.50K | $- | $-22.50K | $- | $53.13K | $- | $-2.50K | $-50.63K | $1.32K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $-2.42K | $- | $- | $- | $4.81K | $28.76K | $10.58K | $13.92K | $-12.17K | $6.82K | $16.84K | $3.33K | $-39.92K | $6.54K | $9.72K | $9.62K | $8.19K |
| Net Cash Used for Investing Activities | $- | $- | $- | $-2.42K | $- | $- | $- | $19.89K | $18.28K | $10.58K | $9.32K | $10.33K | $6.82K | $-5.66K | $3.33K | $13.21K | $6.54K | $7.22K | $-41.01K | $9.51K |
| Debt Repayment | $8.00M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $6.78K | $- | $-6.78K | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $- | $- | $509.73K | $5.00M | $2.90M | $1.33M | $159.51K | $- | $- | $- | $10.77M | $5.00K | $-7.58M | $7.58M | $13.66M | $2.83M | $- | $- | $-6.63M |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-1.40K | $1.97M | $-69.28K | $11.23M | $1.48K | $509.79K | $2.41M | $-144.58K | $- | $- | $- | $- | $- | $402.01K | $7.58M | $- | $- | $2.13M | $- | $6.63M |
| Net Cash Used Provided by Financing Activities | $8.00M | $1.97M | $-69.28K | $11.74M | $5.00M | $3.41M | $3.74M | $6.78K | $- | $- | $6.78K | $10.77M | $-1.78K | $402.01K | $7.58M | $13.66M | $2.83M | $2.13M | $- | $- |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $-26.67K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-193.80K | $-1.87M | $-6.25M | $7.44M | $960.28K | $-73.65K | $-628.24K | $-2.75M | $-3.16M | $-4.35M | $-4.81M | $8.17M | $-3.02M | $-4.04M | $2.66M | $10.61M | $1.23M | $74.90K | $-1.85M | $-2.21M |
| Cash at End of Period | $928.01K | $1.12M | $3.00M | $9.25M | $1.80M | $841.53K | $915.18K | $1.54M | $4.29M | $7.45M | $11.80M | $16.61M | $8.44M | $11.46M | $15.51M | $12.85M | $2.24M | $1.01M | $933.46K | $2.78M |
| Cash at Beginning of Period | $1.12M | $3.00M | $9.25M | $1.80M | $841.53K | $915.18K | $1.54M | $4.29M | $7.45M | $11.80M | $16.61M | $8.44M | $11.46M | $15.51M | $12.85M | $2.24M | $1.01M | $933.46K | $2.78M | $4.99M |
| Operating Cash Flow | $-8.19M | $-3.85M | $-6.18M | $-4.29M | $-4.04M | $-3.48M | $-4.37M | $-2.75M | $-3.18M | $-4.36M | $-4.83M | $-2.61M | $-3.03M | $-4.44M | $-4.93M | $-3.06M | $-1.61M | $-2.06M | $-1.81M | $-2.22M |
| Capital Expenditure | $-3.85M | $3.85M | $- | $-2.42K | $- | $- | $- | $15.09K | $-10.49K | $- | $-4.60K | $22.50K | $- | $-22.50K | $- | $53.13K | $- | $-2.50K | $-50.63K | $1.32K |
| Free Cash Flow | $-12.04M | $-3.85M | $-6.18M | $-4.30M | $-4.04M | $-3.48M | $-4.37M | $-2.73M | $-3.19M | $-4.36M | $-4.83M | $-2.59M | $-3.03M | $-4.46M | $-4.93M | $-3.01M | $-1.61M | $-2.06M | $-1.86M | $-2.22M |
Cyclo Therapeutics Dividends
Explore Cyclo Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Cyclo Therapeutics News
Read the latest news about Cyclo Therapeutics, including recent articles, headlines, and updates.
CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cyclo Therapeutics, Inc. (the “Company”) (NasdaqCM: CYTH) and Rafael Holdings, Inc. (NYSE: RFL). KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to the Company's shareholders. If you would like to discuss your legal rights regarding th.
Cyclo Therapeutics Presents Positive Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label Sub-Study in Patients (< 3 Years Old)
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with rare and challenging diseases, today announced the presentation of data from its ongoing Pivotal Phase 3 global study (TransportNPC™) evaluating Trappsol® Cyclo™ for Niemann-Pick Disease Type C1 (“NPC1”) at the 21st Annual WOR.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LTRPA, LTRPB, CYTH, SKGR on Behalf of Shareholders
NEW YORK , Dec. 20, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Liberty TripAdvisor Holdings, Inc. (OTCMKTS: LTRPA, LTRPB)'s sale to Tripadvisor, Inc. If you are a Liberty TripAdvisor shareholder, click here to learn more about your legal rights and options . Cyclo Therapeutics, Inc. (NASDAQ: CYTH)'s merger with Rafael Holdings, Inc. If you are a Cyclo shareholder, click here to learn more about your rights and options.
Niemann-Pick Disease Pipeline Market Research 2024: Comprehensive Insights about 12+ Drugs Featuring Cyclo Therapeutics, Azafaros, IntraBio
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Niemann-Pick disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering. This "Niemann-Pick disease - Pipeline Insight, 2024," report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Niemann-Pick disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Shareholder Alert: Ademi LLP investigates whether Cyclo Therapeutics, Inc. has obtained a Fair Price for its Public Shareholders
MILWAUKEE , Aug. 23, 2024 /PRNewswire/ -- Ademi LLP is investigating Cyclo Therapeutics (Nasdaq: CYTH) for possible breaches of fiduciary duty and other violations of law in its transaction with Rafael Holdings. Click here to learn how to join our investigation https://www.ademilaw.com/case/cyclo-therapeutics-inc or call Guri Ademi toll-free at 866-264-3995.
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Cyclo Therapeutics, Inc. - CYTH
NEW YORK , Aug. 22, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Cyclo Therapeutics, Inc. (Nasdaq: CYTH), relating to its proposed merger with Rafael Holdings, Inc. Under the terms of the agreement, Cyclo common stock will automatically be converted into the right to receive shares of Rafael common stock.
STOCKHOLDER ALERT: The M&A Class Action Firm Investigates the Mergers of VGR, CYTH
NEW YORK, NY / ACCESSWIRE / August 22, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating: Vector Group Ltd.
Cyclo Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the second quarter 2024 and provided a business update. “The second quarter represents a transformative time for the Company with the achievement of a landmark milestone -- the.
Cyclo Therapeutics Announces Notice of Decision to Grant European Patent Application for Treatment of Alzheimer's Disease from European Patent Office
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that the Company received a notice from the European Patent Office of a decision to grant European patent application No. 19805439.7 titled, “Methods for Treating Alzheimer's Disease” under European p.
Cyclo Therapeutics to Present at the Society for the Study of Inborn Errors of Metabolism (SSIEM) Annual Symposium 2024
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that two abstracts have been accepted for poster presentation at the SSIEM Annual Symposium 2024 being held September 3-6, 2024 in Porto, Portugal. “We truly value the opportunity and are honored to p.
Cyclo Therapeutics Achieves Landmark Milestone with Completion of Enrollment of Last Patient in Phase 3 Pivotal TransportNPC™ Trial of Niemann-Pick Type C1
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the last patient has been enrolled in the Company's pivotal Phase 3 study (“TransportNPC™”) evaluating Trappsol® Cyclo™ for the treatment of systemic and neurological symptoms of Niemann-Pick Disease.
Cyclo Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the first quarter 2024 and provided a business update. “We continue to make progress toward the completion of patient enrollment in our ongoing TransportNPC™ trial. Coupled wi.
Cyclo Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the full year 2023 and provided a business update. “We made significant progress over the course of the past year. We continue to be extremely active with the NPC patient and.
Cyclo Therapeutics Announces Issuance of U.S. Patent Covering the Use of Trappsol® Cyclo™ for the Treatment of Alzheimer's Disease
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 11,925,659 titled, “Methods for Treating Alzheimer's Disease,” with claims that cover the use of Trappsol® Cyclo™ for.
Cyclo Therapeutics Announces Allowance of Patent Application for Treatment of Alzheimer's Disease from the U.S. Patent and Trademark Office
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) regarding Cyclo Therapeutics' U.S. Patent Application No. 17/289,137 titled, “Methods for Tre.
Cyclo Therapeutics, Inc. Completes Merger with Applied Molecular Transport Inc.
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (Nasdaq: AMTI) (“AMT”), a biopharmaceutical company, announced today the closing of its previously announced transaction pursuant to which AMT will merge with Cyclo Therapeutics in an all-stoc.
Cyclo Therapeutics Announces Positive Outcome from Type C Meeting with the U.S. FDA Discussing Trappsol® Cyclo™ Clinical Program for the Treatment of Niemann-Pick Disease Type C1
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, today announced a positive outcome from its recent Type C meeting with the U.S. Food and Drug Administration (FDA), held on Thursday, December 14, 2023 to discuss a full data review of the Company's Trappsol® Cyclo™ clinical deve.
APPLIED MOLECULAR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Applied Molecular Transport Inc. - AMTI
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Applied Molecular Transport Inc. (NasdaqCM: AMTI) to Cyclo Therapeutics, Inc. (NasdaqCM: CYTH). Under the terms of the proposed transaction, shareholders of Applied Molecular will receive 0.174 shares of Cyclo for each share of Applied Molecular that they own. KSF is seeking to determine whether this considera.
Cyclo Therapeutics to Present at the 20th Annual WORLDSymposium™ 2024
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, today announced its abstract has been accepted for platform presentation at the 20th Annual WORLDSymposium™ being held February 4-9, 2024 in San Diego, CA. Details of the platform presentation are as follows: Title: TransportNPC™.
Cyclo Therapeutics Reports Third Quarter 2023 Financial Results
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the third quarter 2023. “Our number one priority remains to be the solid operational execution of our TransportNPC™ study. We are very pleased with our continued strong pace o.
Cyclo Therapeutics Announces Early Exercise of Warrants by Board Members, Management and a Significant Shareholder Resulting in Cash Proceeds of $2.4 Million
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it had entered into a securities purchase agreement with certain accredited investors (the “Investors”) to raise $2,359,584 in a private offering (the “Offering”). The Investors owned vested warr.
Cyclo Therapeutics to Present at 8th Annual Dawson James Conference
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer and Joshua Fine, Chief Financial Officer of Cyclo Therapeutics will present at the 8th Annual Dawson James Conference being held in Jupiter, FL on Thursday,.
CYTH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Cyclo Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Cyclo Therapeutics, Inc. (NASDAQ: CYTH) and Applied Molecular Transport Inc. is fair to Cyclo shareholders. Under the terms of the proposed transaction, Applied Molecular stockholders will receive approximately 0.174 shares of Cyclo for each share of Applied Molecular. Halper Sadeh encourages Cyclo shareholders to click here to learn more about their legal rights and options or conta.
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement
GAINESVILLE, Fla. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company focused on developing transformative therapies for rare and neurological diseases with limited treatment options, and Applied Molecular Transport Inc. (Nasdaq: AMTI) (“AMT”), a biopharmaceutical company, announced today that the companies have entered into a definitive agreement (the Merger Agreement) pursuant t.
Cyclo Therapeutics Reports Second Quarter 2023 Financial Results
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today reported its financial results for the second quarter 2023. “Over the past quarter, we continued to execute on all fronts. We remain focused on driving recruitment in our pivotal TransportNPC™ study of Trappsol.
Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that it has closed the previously announced private placement with Rafael Holdings, Inc. (NYSE:RFL) (“Rafael”) for the purchase of 4,000,000 shares of common stock of Cyclo Therapeutics and warrants t.
Cyclo Therapeutics to Present at the Virtual Investor 2023 Companies to Watch Event
GAINESVILLE, Fla.--( BUSINESS WIRE )--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and families living with diseases, today announced that N. Scott Fine, Chief Executive Officer of Cyclo Therapeutics will present at the Virtual Investor 2023 Companies to Watch Event on Thursday, January 19, 2023 at 11:00 AM ET.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for CYTH.